The SARS-CoV-2/COVID-19 Omicron variant was first identified in November 2021 in Botswana and South Africa (1). Although immunological and clinical data did not provide definitive evidence, the omicron variant displayed early signs of high transmissibility, reduced severity, and immune escape, potentially increasing the difficulty of controlling the pandemic (2,3). In late February 2022, a wave of omicron BA.2 infection rapidly appeared in Shanghai, China. Shanghai is one of the most important international economic, financial, trade, and shipping centers in China, with a resident population of more than 25 million. According to the Shanghai Municipal Health Commission, from February 26 to May 31, 2022, 58,000 cases were reported, and 588 people died with or from the omicron variant of SARS-CoV-2 (4). To reduce the spread of the pandemic, Shanghai imposed a lockdown with movement restrictions, social distancing, and home confinement starting April 1, 2022.Cancer patients endured multiple challenges in terms of infection risk, prognostic outcomes, and tumor recurrence during the COVID-19 pandemic (5). Huang et al. (6) reported that the 30-day mortality was higher in COVID-19 patients with cancer and that patients with both cancer and cardiovascular disease (CVD) have significantly increased Pro-BNP and D-Dimer levels. Dai et al. (7) provided evidence that COVID-19 patients with cancer had a higher risk for all severe outcomes. Patients with hematologic cancer, lung cancer, or with metastatic cancer (stage IV) had the highest frequency of severe events. In addition, delays in early tumor screening, detection, monitoring of recurrence, and treatment may potentially have a negative impact on the outcomes for cancer patients during the COVID-19 pandemic. An observational/modeling study reported